Medical device company Hemovent GmbH reported on Monday the receipt of the CE marking for its MOBYBOX Runner Controller, to market the product throughout the heart and lung support market in the EU.
The company said the Runner is designed to slingshot clinicians into a new era of mobility and ease of use. The device is designed for Extracorporeal Life Support (ECLS) applications, including Extracorporeal CardioPulmonary Resuscitation (ECPR) to treat patients in cardiac arrest or profound circulatory shock.
Following the Runner EU regulatory approval, the company has created an entirely new solution for the extreme challenges of ECLS deployment in situations with unpredictable and severely restricted emergency environments, said Oliver Marseille, PhD, chief technology officer of Hemovent and a co-founder of CircuLite (Heartware International) prior to co-founding Hemovent.
In 2019, the company receive the CE mark for the MOBYBOX System with the Master Controller and is currently in preparing a post market clinical follow-up trial.
GSK wins European Commission approval for Shingrix prefilled syringe
Tri-City Cardiology adds new members to care team
GENinCode expands Mexico presence with CARDIO inCode-Score distribution agreement
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
InsiteOne agrees strategic partnerships with ASCEND Cardiovascular and Apollo Enterprise Imaging
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
LivaNova secures higher Medicare reimbursement for VNS Therapy procedures